<i>In vitro</i> miltefosine susceptibility of parasite isolates from VL and PKDL cases before and after Mil treatment.

<p>Sensitivity of VL and PKDL isolates at intracellular amastigote stage were determined by infection in murine macrophage cell line J774A.1. Each individual value represents mean IC₅₀±SD of the results from two separate assays.</p

Drug susceptibility of <i>Leishmania donovani</i> clinical isolates following Miltefosine treatment in cases of Visceral Leishmaniasis and Post kala-azar dermal Leishmaniasis.

1<p>WHO code: country and year of isolation and the respective strain code, the number following the isolate ID indicates the number of months elapsed after start of MIL treatment.</p>2<p>Research code: Parasites cultured from VL patients were labeled V- and from PKDL patients P-, respectively. The number following the isolate ID indicates the number of months elapsed after start of MIL treatment (e.g. V902/1 means one month passed from first MIL treatment). Parasites isolated from patients' prior start of MIL treatment were labeled as XXX/0 and one month following first treatment was labeled XXX/1. These patients cleared from VL symptoms after respective duration of MIL treatment and were interpreted as clinical cure, although residual parasites could be cultured from splenic aspirates (marked XXX/1). In the period of 1 year follow up, cases of relapse were observed in three VL patients that had shown an initial clinical cure, the isolates obtained were designated as XXX/month in which relapse occurred.</p><p>Cure*- Patients treated with SAG (1000 mg intra muscularly), daily for four months.</p